When I first began paying attention to exchange-traded funds, I viewed them as financial plumbing. They were useful, efficient, and not particularly exciting. An ETF allowed me to buy a basket of securities without selecting every stock or bond myself, and that seemed like a sensible improvement over building a portfolio one company at a time. What I did not fully appreciate was that the plumbing would eventually become some of the most valuable infrastructure in global finance. ETFs have moved from the margins of investing to the center of it. They sit in retirement accounts, brokerage portfolios, institutional strategies, model portfolios, robo-advisory platforms, and short-term trading systems. They are used by people investing $50 from a paycheck and institutions moving billions of dollars before lunch. BlackRock, through its iShares franchise, has become one of the clearest beneficiaries of this transformation. By the end of 2025, BlackRock had approximately $14 trillion in total ...
I have a complicated relationship with biotech stocks. I love the science, the unmet medical needs, and the possibility that one successful medicine can change both patients’ lives and a company’s value. I am less fond of waking up to discover that a clinical trial missed its primary endpoint and half my investment has evaporated before I have located the coffee. That is the biotech bargain. Investors are invited to study molecular targets, trial designs, competitive landscapes, safety profiles, and regulatory pathways. Then a press release arrives at 7:00 a.m. and reduces years of careful analysis to one merciless word: met or missed. This is why ACADIA Pharmaceuticals catches my attention. ACADIA, which trades under the ticker ACAD, does not fit neatly into the familiar small-biotech stereotype. It is not a pre-revenue company living from financing round to financing round while asking shareholders to remain patient for another eighteen months. It already sells two FDA-approved medic...